Baudax Bio, Inc. (BXRX)

NASDAQ: BXRX · IEX Real-Time Price · USD
3.41
+0.12 (3.65%)
At close: Feb 7, 2023, 4:00 PM
3.48
+0.07 (2.05%)
After-hours: Feb 7, 2023, 7:54 PM EST
3.65%
Market Cap 1.89M
Revenue (ttm) 1.36M
Net Income (ttm) -22.53M
Shares Out 554.88K
EPS (ttm) 250.80
PE Ratio 0.01
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 336,631
Open 3.21
Previous Close 3.29
Day's Range 3.11 - 3.44
52-Week Range 1.55 - 280.00
Beta 1.58
Analysts Sell
Price Target 24.48 (+617.89%)
Earnings Date Mar 15, 2023

About BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intran... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Geraldine A. Henwood Ph.D.
Employees 80
Stock Exchange NASDAQ
Ticker Symbol BXRX
Full Company Profile

Financial Performance

In 2021, Baudax Bio's revenue was $1.08 million, an increase of 119.07% compared to the previous year's $493,000. Losses were -$22.19 million, -70.84% less than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for BXRX stock is "Sell." The 12-month stock price forecast is $24.48, which is an increase of 617.89% from the latest price.

Price Target
$24.48
(617.89% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Is the Pain Over for Baudax Bio Investors after a 70% Spike?

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20...

1 week ago - MarketBeat

Why Is Baudax Bio (BXRX) Stock Up 50% Today?

What caused Baudax Bio (NASDAQ: BXRX) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000...

2 weeks ago - InvestorPlace

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful...

2 weeks ago - GlobeNewsWire

The 7 Most Sold-Off Stocks of 2022

With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to gar...

Other symbols: ATNFCVNADBGIEMBKFUVMF
1 month ago - InvestorPlace

Why Is Baudax Bio (BXRX) Stock Up 46% Today?

Baudax Bio (NASDAQ: BXRX) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the company's drug candidate for neuromuscular b...

2 months ago - InvestorPlace

Baudax's stock rallies after announcing start to Phase 2 clinical trial

Shares of Baudax Bio Inc. BXRX, +20.77% soared 62.6% in premarket trading on Friday, the day after the company said it started a Phase 2 clinical trial evaluating an experimental treatment for neuromu...

2 months ago - Market Watch

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation...

2 months ago - GlobeNewsWire

Baudax Bio Announces Closing of $5 Million Public Offering

MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settin...

2 months ago - GlobeNewsWire

Baudax Bio Announces Pricing of $5 Million Public Offering

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today annou...

2 months ago - GlobeNewsWire

Baudax Bio Announces 1-for-40 Reverse Stock Split

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Compa...

2 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

BX 1000 Phase II Trial Underway

3 months ago - GlobeNewsWire

New Strong Buy Stocks for October 27th

BXRX, SSB, IBA, CATY and KOF have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2022.

Other symbols: CATYIBAKOFSSB
3 months ago - Zacks Investment Research

New Strong Buy Stocks for October 24th

BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.

Other symbols: BHRGHRSRKDAWOLF
3 months ago - Zacks Investment Research

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings, today...

5 months ago - GlobeNewsWire

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, th...

5 months ago - GlobeNewsWire

Baudax Bio Announces Closing of $6.2 Million Public Offering

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announ...

5 months ago - GlobeNewsWire

Baudax Bio Announces Pricing of $6.2 Million Public Offering

MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announc...

5 months ago - GlobeNewsWire

Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain

MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced today that the United States Patent ...

6 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) Reports Q2 Loss, Misses Revenue Estimates

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of 17.32% and 61.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

ANJESO ® Net Product Revenue Up 49% Year-Over-Year ; Vials Sold to End-Users Up 67% Year-Over-Year

6 months ago - GlobeNewsWire

Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #CFO--Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer...

7 months ago - Business Wire

Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the ...

9 months ago - GlobeNewsWire

Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it ...

9 months ago - GlobeNewsWire

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

Annual Meeting to be reconvened on May 18, 2022 Annual Meeting to be reconvened on May 18, 2022

9 months ago - GlobeNewsWire